logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Reports Phase 3 Topline Trial Results Of Iniparib & Otamixaban

Sanofi (SNYNF,SNY) announced topline results of two Phase 3 studies of its investigational compounds iniparib and otamixaban respectively.

The randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer failed to meet its primary endpoint. During the study, newly diagnosed, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone.

Topline results of the completed Phase 3 trial of the investigational anticoagulant otamixaban demonstrated that the study failed to meet its primary endpoint of superiority over current therapy. In the TAO study, due to efficacy lower than expected, otamixaban did not show superior benefit/risk to the combination of unfractionated heparin (UFH) +/- eptifibatide (a GP IIb/IIIa inhibitor) in non-ST elevation acute coronary syndrome patients planned for early invasive strategy. The primary endpoint of the Phase 3 TAO trial was the reduction of all-cause mortality or new heart attacks.

As a result, the company would terminate the investigational program with otamixaban, an injectable factor Xa inhibitor.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Amazon.com Inc. intends to bring its free same-day delivery to the Bronx and Chicago's South Side areas. The online retailer's plans comes after severe criticism were raised that the company unfairly left out some predominantly black and Hispanic areas from its Prime service. An analysis done by... Sprint Corp., the third largest U.S. wireless carrier, on Tuesday reported a loss for the fourth quarter that widened from last year on one-time charges and lower revenues. The latest quarter's results include charges related to severance and lease exit costs, including the shutdown of legacy WiMAX service that will free up valuable spectrum and immediately lower network costs. Shares of Infineon Technologies AG were losing around 4 percent in German trading after the manufacturer of semiconductors and system solutions reduced its revenue growth forecast for fiscal 2016. This was despite a surge in second-quarter profit with strong revenues. For the third quarter, the company projects revenue growth sequentially.
comments powered by Disqus
Follow RTT